Dexcom Tops Quarterly Expectations And Keeps Its Guidance. But Shares Crash.

Dexcom (DXCM) stock crashed late Thursday though the diabetes devices player beat Wall Street's third-quarter expectations and reiterated its outlook for the year.

↑ X NOW PLAYING How To Buy Stocks: Profit From Earnings Reports Using This Option Strategy

In the September quarter, Dexcom earned an adjusted 45 cents a share, beating expectations by two pennies. Earnings dipped 14% year over year. Sales edged 2% higher to $994.2 million, topping the Street view for $990 million, according to FactSet.

Organically, sales advanced 3% vs. the year-ago period.

Dexcom also reiterated its guidance for the year. The company calls for $4 billion to $4.05 billion in sales, vs. analysts' projection for $4.01 billion. That represents 11% to 13% organic sales growth.

In after-hours trades, Dexcom stock plunged more than 13% to 64.60.

More to follow.

Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.

YOU MAY ALSO LIKE:

Boston Scientific's Rockstar Segment Just Fumbled — And So Did Its Shares

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Join IBD Live For Stock Ideas Each Morning Before The Open

Learn How To Time The Market With IBD's ETF Market Strategy

Find Today's Best Growth Stocks To Watch With IBD 50